Anaplastic thyroid carcinoma with long term survival after combined treatment: case report

Endocr Regul. 2007 Mar;41(1):41-4.

Abstract

Anaplastic thyroid carcinoma (ATC) is associated with an almost uniformly rapid and lethal clinical course. ATC grows rapidly and invades surrounding tissues at an early stage. Despite surgery, chemotherapy and radiotherapy, few patients with ATC live more than 1 year follow-up diagnosis. The mean survival is reported to be only 7.2 months. Treatment of ATC is still controversial because of its rarity and advanced stage at the time of diagnosis. We report herein an unusual case of ATC, 35 year old woman. She is alive without evidence of recurrence more than 36 months after combined therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma / drug therapy*
  • Carcinoma / radiotherapy*
  • Carcinoma / surgery
  • Combined Modality Therapy
  • Disease-Free Survival
  • Docetaxel
  • Female
  • Humans
  • Radiation-Sensitizing Agents / therapeutic use
  • Radiotherapy, Adjuvant
  • Taxoids / therapeutic use*
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / radiotherapy*
  • Thyroid Neoplasms / surgery
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Radiation-Sensitizing Agents
  • Taxoids
  • Docetaxel